Unusual Epigenetic Modifier Drives Some Cancers While Inhibiting Others

In a remarkable breakthrough, researchers at Rockefeller University have unveiled novel insights into the epigenetic modifier MLL4, a protein complex with paradoxical roles in cancer biology. While MLL4 propels disease progression in certain leukemias, it paradoxically suppresses solid tumors, functioning in concert with the crucial tumor-suppressor protein p53. This discovery sheds new light on the multifaceted mechanisms governing gene regulation and cancer.

MLL4 belongs to the mixed-lineage leukemia (MLL) family of histone lysine methyltransferases, enzymes that particularly methylate histone H3 at lysine 4 (H3K4), a modification pivotal for activating gene transcription. Notably, MLL4 is the largest nuclear protein in mammalian cells and serves as a transcriptional cofactor essential for tissue differentiation, development, and context-dependent regulation of cancer-related genes.

The pioneering work led by Robert Roeder’s Laboratory of Biochemistry and Molecular Biology employed an innovative combination of cryo-electron microscopy (cryo-EM), genetics, and a sophisticated in vitro transcription system developed in their lab to resolve the full nine-subunit architecture of MLL4, including five unique components. The high-resolution structural data revealed that MLL4 anchors rigidly to nucleosomes but extends a flexible arm to recognize histone targets for methylation, effectively switching genes on.

Strikingly, the researchers discovered a unique intramolecular fold where MLL4’s N-terminal region folds back onto its C-terminal domain, forming a structural architecture essential not only for histone methylation but also for facilitating p53-dependent transcriptional activation. Genetic knockout experiments demonstrated that deleting MLL4 impairs transcription of p53 target genes, which are vital for genome protection mechanisms such as DNA repair, cell cycle arrest, and apoptosis.

This newfound co-activator role of MLL4 in assisting p53’s function signifies a second, distinct mechanism by which MLL4 influences gene regulation, beyond its canonical methyltransferase activity. The collaboration between MLL4 and p53 underscores a complex regulatory network that balances oncogenic and tumor-suppressive signals depending on cellular context.

The study’s implications are far-reaching, offering a molecular explanation for MLL4’s dualistic behavior in leukemia and solid tumors. Moving forward, the team aims to elucidate how MLL4 interacts with other leukemia-associated transcription factors, potentially unveiling therapeutic targets that exploit its context-dependent functions.

This research not only deepens our understanding of epigenetic regulation but also highlights MLL4 as a critical modulator in cancer biology, making it a compelling focus for future cancer therapies and transcriptomic studies.